These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11161396)

  • 1. Low interleukin-1alpha messenger RNA levels predict decreased overall survival time of patients with urinary bladder carcinoma.
    Seddighzadeh M; Steineck G; Jansson O; Larsson P; Wijkström H; Adolfsson J; Portwood N; Hansson J; Linder S
    Br J Cancer; 2001 Feb; 84(3):329-34. PubMed ID: 11161396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
    Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
    Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
    BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.
    Champelovier P; Boucard N; Levacher G; Simon A; Seigneurin D; Praloran V
    Urol Res; 2002 Oct; 30(5):301-9. PubMed ID: 12389118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
    Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
    J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
    Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
    Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma.
    Casella R; Shariat SF; Monoski MA; Lerner SP
    Cancer; 2002 Dec; 95(12):2494-9. PubMed ID: 12467062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.
    Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY
    Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
    Warnecke-Eberz U; Prenzel KL; Baldus SE; Metzger R; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
    Pancreas; 2008 Mar; 36(2):173-7. PubMed ID: 18376309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of IL-1alpha on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in osteoblastic ROS 17/2.8 cells.
    Fujisaki K; Tanabe N; Suzuki N; Mitsui N; Oka H; Ito K; Maeno M
    Life Sci; 2006 Mar; 78(17):1975-82. PubMed ID: 16313928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
    Kusuda T; Shigemasa K; Arihiro K; Fujii T; Nagai N; Ohama K
    Oncol Rep; 2005 Jun; 13(6):1153-8. PubMed ID: 15870936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
    Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
    Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence.
    Schultz IJ; Kiemeney LA; Witjes JA; Schalken JA; Willems JL; Swinkels DW; de Kok JB
    Anticancer Res; 2003; 23(4):3327-31. PubMed ID: 12926071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder.
    Christoph F; Weikert S; Wolff I; Schostak M; Tabiti K; Müller M; Miller K; Schrader M
    Cancer Lett; 2007 Jan; 245(1-2):121-6. PubMed ID: 16473461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer.
    Takihana Y; Tsuchida T; Fukasawa M; Araki I; Tanabe N; Takeda M
    Int J Urol; 2006 Apr; 13(4):401-8. PubMed ID: 16734859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
    Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
    Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
    Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.